Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics Trading under DCOY to commence on January 8, 2026 Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient 2026 plan features advancing lead antiviral into the clinic while expanding pipeline and

#SLRX Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

www.stocktitan.net/news/SLRX/salarius-pharm...

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on December 19, 2025 has been adjourned for the purpose of

#SLRX Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

www.stocktitan.net/news/SLRX/salarius-pharm...

Most Searched, Wednesday December 3, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Dec 3rd - #RXRX #PMAX #POET #ALIT #BTBT #ABTC #GENI #QCLS #CAPR #SLRX #RR #PLUG #ONDS #KITT #DC #BYND #BTTC #SERV #AEVA - More: crystalequityresearch.com/most-searche... - #smallcap

#SLRX Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

www.stocktitan.net/news/SLRX/salarius-pharm...

Trade Alerts, Monday November 24, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Mon Nov 24th - #YDES #HSAI #VOR #SLRX #NXTC #MXL #ENLV #CLLS #BLFY #AEHL #MAGN #GNK #CMDB #BFLY - More: crystalequityresearch.com/trade-alerts... - #smallcap

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP 3 ACT™ platform Combined company has pro forma cash of $14 million following merger and closing of recent public offering HOUSTON and

#SLRX Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

www.stocktitan.net/news/SLRX/salarius-pharm...

📢 Stocks Trending NOW: #AMD #CRCL #ONON #MRK #CMCT #MRNA #AMZE #MKC #JMIA #SLRX

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering HOUSTON, Nov. 11, 2025/ PRNewswire/-- Salarius Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting discounts and commissions and other offering expenses. The offering is comprised of 2,514,335 shares of its common stock and pre-funded warrants to...

#SLRX Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

www.stocktitan.net/news/SLRX/salarius-pharm...

Cancer Drug Developer Salarius Launches Stock Consolidation to Meet Nasdaq Requirements Biotech firm implements 1-for-15 share consolidation effective Aug 18, reducing outstanding shares to 509,000. Move aims to meet Nasdaq's $1 minimum bid requirement. Learn more.

#SLRX Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

www.stocktitan.net/news/SLRX/salarius-pharm...

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard Salarius Pharmaceuticals (Nasdaq: SLRX) has received an additional extension from Nasdaq to regain compliance with two critical listing requirements by late July/early August 2025. The company must meet the $2.5 million minimum stockholders' equity requirement and the $1.00 minimum bid price requirement to maintain its Nasdaq listing.This extension follows Salarius' January 2025 announcement of a definitive merger agreement with Decoy Therapeutics, a private preclinical biopharmaceutical company. Upon completion, the merged entity will operate as Decoy Therapeutics, focusing on peptide conjugate therapeutics development.

#SLRX Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

www.stocktitan.net/news/SLRX/salarius-pharm...

Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise Latest research validates Seclidemstat's cancer-fighting mechanism. Phase 1/2 trial progresses at MD Anderson while merger with Decoy Therapeutics advances. See results.

#SLRX Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

www.stocktitan.net/news/SLRX/salarius-pharm...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Tue Jun 17th - #WTF #VERV #SLRX #RELI #PCT #NETD #MINM #INV #GALT #FEIM #AIP #HYAC #PACS #BGSF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Revolutionary AI Platform Discovers Multi-Target Antiviral in Just 5 Days Decoy's AI-powered IMP3ACT platform rapidly identifies novel antivirals effective against measles, Nipah, RSV, and hPIV3. Full breakthrough analysis inside.

#SLRX Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

www.stocktitan.net/news/SLRX/salarius-pharm...

Salarius Slashes Annual Losses While Pursuing Game-Changing Merger Deal Biotech firm reduces losses to $5.6M while advancing Decoy Therapeutics merger and Phase 1/2 cancer trial. Strategic pivot promises enhanced drug development.

#SLRX Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/SLRX/salarius-pharm...

Salarius Pharma Merges with AI Drug Designer Decoy Therapeutics, Plans Pan-Coronavirus Drug Salarius Pharmaceuticals combines with Decoy Therapeutics, integrating AI-driven drug design platform IMP3ACT™. Combined entity targets respiratory viruses and cancer therapeutics development.

#SLRX Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

www.stocktitan.net/news/SLRX/salarius-pharm...

Breaking News: ( NASDAQ: #SLRX ) Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) Near the Top of Equities by Percentage Gain on 7/25

#StockMarket #News

JUST IN: ( NASDAQ: #SLRX ) US Companies Moving the Markets, Morning edition <br>Thu, Jul 25, 2024 as of 10.00 am ET

#StockMarket #News

Just In: ( NASDAQ: #SLRX ) Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) Near the Top of Equities by Percentage Gain on 7/23

#StockMarket #News